Qurient Co., Ltd. (KOSDAQ:115180)

South Korea flag South Korea · Delayed Price · Currency is KRW
39,550
-1,450 (-3.54%)
At close: Apr 28, 2026
287.75%
Market Cap 1.60T
Revenue (ttm) 6.98B
Net Income (ttm) -30.05B
Shares Out 40.42M
EPS (ttm) -880.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,279
Average Volume 201,624
Open 40,200
Previous Close 41,000
Day's Range 38,900 - 40,250
52-Week Range 9,100 - 62,900
Beta 0.57
RSI 53.29
Earnings Date May 12, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 115180
Full Company Profile

Financial Performance

In 2025, Qurient's revenue was 6.98 billion, a decrease of -23.94% compared to the previous year's 9.18 billion. Losses were -30.05 billion, 24.6% more than in 2024.

Financial Statements

News

There is no news available yet.